Table 1 Baseline demographics and patient characteristics (N=20)

From: A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

Age, years

Median

54

Range

18–87

Gender, n (%)

Male

10 (50)

Female

10 (50)

ECOG score, n (%)

0

4 (20)

1

16 (80)

Tumour type, n (%)

Colorectal

6 (30)

Renal cell

3 (15)

Leiomyosarcoma

3 (15)

Other

8 (40)

Previous therapies

Systemic therapy

19 (95)

Antiangiogenic agents

11 (55)

Radiotherapy

12 (60)

  1. Abbreviation: ECOG=Eastern Cooperative Oncology Group.
Back to article page